A5006566372- Kruppel-like factors research
- Chronic Myeloid Leukemia Treatments
- CAR-T cell therapy research
- Acute Lymphoblastic Leukemia research
- Immune Cell Function and Interaction
- Nanowire Synthesis and Applications
- Genomics, phytochemicals, and oxidative stress
- Immunotherapy and Immune Responses
- Virus-based gene therapy research
- Acute Myeloid Leukemia Research
- Cancer-related gene regulation
- RNA Interference and Gene Delivery
- Myeloproliferative Neoplasms: Diagnosis and Treatment
- T-cell and Retrovirus Studies
- Childhood Cancer Survivors' Quality of Life
- Cancer Immunotherapy and Biomarkers
- Transgenic Plants and Applications
- Chronic Lymphocytic Leukemia Research
- Synthesis and biological activity
- Neutropenia and Cancer Infections
- Adolescent and Pediatric Healthcare
- Glutathione Transferases and Polymorphisms
- Neuropeptides and Animal Physiology
- Immune cells in cancer
- Synthesis and Characterization of Heterocyclic Compounds
Chulalongkorn University
2015-2025
King Chulalongkorn Memorial Hospital
2022
Texas Children's Hospital
2010-2019
Baylor College of Medicine
2010-2018
Children's Cancer Center
2010-2016
Acute lymphoblastic leukemia (ALL) is the most common hematological cancer in children. Although risk-adaptive therapy, CNS-directed chemotherapy, and supportive care have improved survival of ALL patients, disease relapse still leading cause cancer-related death Therefore, new drugs are needed as frontline treatments high-risk salvage agents relapsed ALL. In this study, we report that purified sulforaphane, a natural isothiocyanate found cruciferous vegetables, has anti-leukemic properties...
Triple-negative breast cancer (TNBC) is characterized by excessive accumulation of tumor-infiltrating immune cells, including tumor-associated macrophages (TAMs). TAMs consist a heterogeneous population with high plasticity and are associated tumor aggressiveness poor prognosis. Moreover, cells can secrete factors that influence TAM polarization. Therefore, this study aimed to evaluate the crosstalk between in context TNBC. Cytokine-polarized M2 macrophage were used as control. Distinct from...
Abstract CAR-T-cell therapy has shown promise in treating hematological malignancies but faces challenges solid tumors due to impaired T-cell function the tumor microenvironment. To provide optimal activation, we developed a B7 homolog 3 protein (B7H3)-targeting CAR construct consisting of three activation signals: CD3ζ (signal 1), 41BB 2), and interleukin 7 receptor alpha (IL7Rα) cytoplasmic domain 3). We generated B7H3 CAR-T cells with different lengths IL7Rα domain, including full length...
Background A bidirectional promoter-driven chimeric antigen receptor (CAR) cassette provides the simultaneous expression of two CARs, which significantly enhances dual antigen-targeted CAR T-cell therapy. Methods We developed a second-generation directing CD19 and CD20 antigens, incorporating them in head-to-head orientation from promoter using single Sleeping Beauty transposon system. The efficacy T cells was determined vitro against cell lines expressing either, or both, antigens. In vivo...
Background B7 homolog 3 (B7-H3), an overexpressed antigen across multiple solid cancers, represents a promising target for CAR T cell therapy. This study investigated the expression of B7-H3 various tumors and developed novel monoclonal antibodies (mAbs) targeting Methods Expression was evaluated using RNA-seq data from TCGA, TARGET, GTEx datasets by flow cytometry staining. B7-H3-specific mAbs were immunizing mice with human B7-H3, screening ELISA, analyzing kinetics surface plasmon...
Abstract Advances made in chimeric antigen receptor (CAR) T cell therapy have revolutionized the treatment and management of certain cancers. Currently, B malignancies been among few cancers to which CAR cells shown persistent resilient anti‐tumor responses. A growing body evidence suggests that persistence within patients following infusion is linked mitochondrial fitness cell, could affect clinical outcomes. Analysis from undergoing successful has an increase mass fusion events, a...
Adoptive cellular therapy with chimeric antigen receptor (CAR) T cells has emerged as a potential novel treatment for various cancers. In this study, we have generated CAR targeting mucin-1 (MUC1), which is an aberrantly glycosylated overexpressed on breast cancer cells. Two different signaling domains, including CD28 and 41BB, were incorporated directly compared the superiority of costimulatory signals. MUC1 constructs transduced into primary evaluated their characteristics antitumor...
CD19-chimeric antigen receptor (CAR) T cell therapy is a promising immunotherapy for cancer treatment that has shown remarkable clinical responses, leading to approval by the FDA relapsed and refractory B hematological malignancy treatment. Cannabidiol (CBD) nonpsychoactive cannabinoid compound been utilized as palliative in patients due its immunosuppressive properties. Currently, studies on using CBD during have gained increasing attention. However, possible interaction between CAR not...
Background: Cytokine-induced killer (CIK) cells are a heterogeneous group of immune that exert potent MHC-unrestricted cytotoxicity toward various cancer in both solid and hematological malignancies. Objective:The purposes this study were to compare the expansion characteristics cytokine-induced between standard culture method gas-permeable develop clinical-scale protocol for using method. Methods:We compared absolute cell number, fold change, subsets, activation markers, cytokine...
Abstract Acute lymphoblastic leukemia is the most common hematological malignancy in pediatric patients, and disease relapse leading cause of cancer-associated death children. Despite steadily improved outcomes patients with newly diagnosed disease, little progress has been made to treat reduce incidence by increasing cure rates frontline therapy. Targeted therapy currently not available for T-ALL development novel agents requires a better understanding how leukemia-initiating cells (LIC)...
Abstract Chronic myeloid leukemia (CML) is the first blood cancer known to originate from a single hematopoietic stem cell (HSC) by expression of BCR-ABL, product chromosomal translocation t(9;22), that slowly progress lethal fast-growing caused malignant reprogramming progenitor cells (blast crisis). Although CML can be successfully managed with targeted therapy suppressing BCR-ABL kinase activity tyrosine inhibitors (TKI), patients remain in remission as long they adhere lifelong...
Abstract T-cell acute lymphoblastic leukemia (T-ALL) is an aggressive hematological malignancy with the highest incidence of relapse any pediatric ALL. A minimal two-hit model leukemogenesis suggests that initial genetic driver transforms hematopoietic progenitor cells into LICs, whereas a secondary alteration would endow LICs proliferative and survival advantages. Although most T-ALL patients exhibit activating mutations in NOTCH1, cooperating events required to accelerate onset worsen...